Key result
Children with type 1 diabetes and clinically significant C-peptide levels had significantly higher betatrophin concentrations compared to those with insignificant levels, indicating a positive correlation between betatrophin and residual beta-cell function.
Why the study?
Maintaining endogenous insulin secretion in T1D long after onset has made identifying factors that preserve beta-cell secretory function an important research goal.
Cross-Sectional (n=121)
No
Absolute Event Rate: 8.318% vs 5.85%
p-value: p=0.019
Betatrophin may serve as a potential biomarker of long-lasting residual beta-cell function in children with type 1 diabetes, and its negative correlation with BMI highlights the importance of maintaining appropriate body weight.
Betatrophin may mark residual β-cell function in pediatric T1D; hypothesis-generating observational link requires prospective validation before clinical use.
Introduction: Maintaining endogenous insulin secretion in type 1 diabetes (T1D) long after its onset, and thus the need for early diagnosis and searching for factors preserving the secretory function of β-cells, has become an important goal of current research. The aim of the study was to evaluate C-peptide secretion in T1D children with at least 1 year disease duration and to investigate the potential role of body mass index (BMI) and betatrophin on residual β-cell function. We also assessed factors that may affect betatrophin levels. Methods: 121 children and adolescents suffering from T1D were divided into groups based on: clinical significance of C-peptide; BMI-SDS <1 and ≥1; and disease duration to compare C-peptide and betatrophin levels and determine the importance of these changes. Results: Of the children recruited, 44 (36.36%) had clinically significant C-peptide (> 0.23 ng/ml), and compared with the group with clinically insignificant C-peptide they had later onset (P<.001), shorter duration of illness (P<.001), lower daily insulin requirement (P=.025), lower mean HbA1c over the past year (P=.002), higher betatrophin levels (P=.019), and BMI-SDS at diagnosis (P=.013). Betatrophin levels correlated positively with C-peptide (P=.043) while negatively with patient's age (P<.001), BMI-SDS (P=.010), disease duration (P=.006), HbA1c level at sampling (P=.022), average HbA1c level over the past year (P=.006), and basal insulin (P=.001). Conclusion: The positive significant relationship between betatrophin and C-peptide concentrations may indicate betatrophin as a potential biomarker of long-lasting residual β-cell function. Negative correlation with BMI identifies the ongoing need to maintain an appropriate body mass.
No takes yet. Share an insight, caveat, or question.
Odyjewska et al. (2025) conducted a cross-sectional in Type 1 diabetes (n=121). Clinically significant C-peptide (>0.23 ng/ml) vs. Clinically insignificant C-peptide was evaluated on Betatrophin concentration (ng/ml) (p=0.019). Children with type 1 diabetes and clinically significant C-peptide levels had significantly higher betatrophin concentrations compared to those with insignificant levels, indicating a positive correlation between betatrophin and residual beta-cell function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: